Your browser is no longer supported. Please, upgrade your browser.
Settings
CALA Calithera Biosciences, Inc. daily Stock Chart
CALA [NASD]
Calithera Biosciences, Inc.
Index- P/E- EPS (ttm)-1.74 Insider Own0.10% Shs Outstand64.56M Perf Week6.28%
Market Cap370.08M Forward P/E- EPS next Y-1.28 Insider Trans-96.92% Shs Float62.69M Perf Month-4.15%
Income-90.60M PEG- EPS next Q-0.34 Inst Own72.90% Short Float4.66% Perf Quarter-27.64%
Sales- P/S- EPS this Y-27.30% Inst Trans-2.77% Short Ratio4.14 Perf Half Y-19.87%
Book/sh1.98 P/B2.57 EPS next Y8.60% ROA-57.40% Target Price- Perf Year27.64%
Cash/sh1.85 P/C2.74 EPS next 5Y- ROE-68.40% 52W Range2.45 - 8.18 Perf YTD-11.03%
Dividend- P/FCF- EPS past 5Y16.50% ROI- 52W High-37.90% Beta2.13
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low107.35% ATR0.24
Employees93 Current Ratio8.80 Sales Q/Q- Oper. Margin- RSI (14)49.54 Volatility4.58% 4.63%
OptionableYes Debt/Eq0.00 EPS Q/Q37.90% Profit Margin- Rel Volume0.60 Prev Close5.00
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume705.05K Price5.08
Recom1.30 SMA20-0.26% SMA50-3.94% SMA200-5.21% Volume427,370 Change1.60%
Mar-27-20Initiated Jefferies Buy $6
Nov-19-19Initiated H.C. Wainwright Buy $7
May-30-19Resumed Citigroup Buy
Feb-16-18Upgrade Citigroup Neutral → Buy
Oct-05-17Initiated William Blair Outperform
Apr-03-17Resumed Leerink Partners Outperform
Mar-28-17Reiterated H.C. Wainwright Buy $10 → $14
Jan-24-17Upgrade Citigroup Sell → Neutral
Jan-05-17Initiated H.C. Wainwright Buy $9
Oct-25-16Initiated Citigroup Sell
Jul-24-15Initiated Citigroup Buy
Aug-03-20 07:01AM  
Jul-28-20 07:00AM  
Jul-14-20 07:00AM  
Jul-13-20 07:00AM  
Jul-06-20 08:05AM  
Jul-02-20 07:00AM  
Jun-02-20 07:00AM  
May-29-20 08:00AM  
May-27-20 07:01AM  
May-26-20 12:34AM  
May-18-20 11:30AM  
May-13-20 09:15AM  
May-11-20 12:00PM  
May-08-20 01:01PM  
May-07-20 04:05PM  
May-06-20 07:05AM  
May-01-20 09:57AM  
Apr-30-20 07:01AM  
Apr-20-20 04:05PM  
Apr-16-20 12:18AM  
Apr-15-20 04:01PM  
Apr-14-20 08:48AM  
07:00AM  
Apr-13-20 11:14AM  
Apr-07-20 09:30AM  
Mar-30-20 05:15PM  
Mar-28-20 09:09AM  
Mar-11-20 04:10PM  
03:00PM  
Mar-04-20 07:05AM  
Feb-19-20 07:05AM  
Jan-30-20 09:38AM  
Jan-13-20 07:07AM  
Jan-03-20 07:05AM  
Dec-13-19 02:46PM  
Dec-06-19 07:05AM  
Dec-05-19 07:05AM  
Dec-04-19 08:20PM  
Dec-02-19 11:38AM  
Nov-12-19 04:06PM  
Nov-05-19 08:01AM  
Nov-04-19 08:00AM  
Oct-19-19 09:23AM  
Oct-18-19 10:23AM  
Oct-07-19 09:54AM  
Oct-03-19 07:05AM  
Oct-01-19 04:05PM  
Sep-29-19 10:30AM  
Sep-28-19 02:30AM  
Sep-27-19 09:28AM  
Sep-26-19 06:05PM  
12:00PM  
Sep-25-19 08:05AM  
Sep-19-19 10:06AM  
Sep-09-19 09:38PM  
Aug-28-19 08:00AM  
Aug-23-19 09:11AM  
Aug-08-19 04:05PM  
Aug-01-19 07:07AM  
Jul-24-19 10:40AM  
Jul-02-19 08:00AM  
Jun-27-19 07:15PM  
Jun-21-19 04:04PM  
Jun-18-19 11:00PM  
01:16PM  
Jun-17-19 04:01PM  
10:08AM  
10:04AM  
06:00AM  
May-23-19 11:24PM  
May-14-19 12:34PM  
May-10-19 05:14AM  
May-09-19 04:06PM  
May-02-19 10:32AM  
Apr-25-19 07:34AM  
Apr-02-19 07:05AM  
Mar-27-19 05:39PM  
Mar-26-19 07:05AM  
Mar-13-19 01:30PM  
Mar-07-19 04:06PM  
Mar-05-19 07:05AM  
Mar-04-19 07:05AM  
Feb-27-19 04:35PM  
Feb-22-19 08:00AM  
Feb-21-19 04:05PM  
Feb-16-19 06:00AM  
Feb-04-19 07:05AM  
Jan-28-19 07:30AM  
Jan-18-19 02:19PM  
Jan-07-19 07:05AM  
Nov-30-18 08:00AM  
Nov-21-18 09:50AM  
Nov-19-18 09:31PM  
Nov-09-18 08:10AM  
Nov-07-18 08:35PM  
07:32PM  
04:05PM  
Oct-31-18 08:00AM  
Oct-15-18 08:55AM  
Oct-05-18 01:06PM  
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerMay 21Sale6.002,283,59813,701,588480,432May 26 05:52 PM
Wong StephanieSR. VP, FINANCE & SECRETARYApr 15Sale8.005,00040,00030,082Apr 17 04:05 PM
Orford KeithChief Medical OfficerFeb 20Sale8.003,02124,1688,541Feb 24 04:05 PM
Orford KeithChief Medical OfficerDec 23Sale6.003,02118,12611,562Dec 26 04:01 PM
BVF PARTNERS L P/IL10% OwnerNov 20Buy3.91191,954750,8474,739,356Nov 22 07:53 PM
BVF PARTNERS L P/IL10% OwnerNov 14Buy3.37128,488433,0054,640,838Nov 18 06:38 PM
BVF PARTNERS L P/IL10% OwnerOct 30Buy2.70797,5082,153,2724,569,343Oct 31 06:27 PM
BVF PARTNERS L P/IL10% OwnerOct 29Buy2.601,598,9774,157,3404,160,751Oct 31 06:27 PM